Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MYSTIC Trial Analysis IDs Mutations Prognostic of mNSCLC Outcomes

Key clinical point: Mutations in certain tumor suppressor genes are prognostic for OS in mNSCLC.

Major finding: ORRs for durvalumab + tremelimumab treated patients with ARID1am vs. ARID1awt were 51.3% vs. 19.4%, respectively.

Study details: An analysis of 943 samples from the open-label phase 3 MYSTIC trial.

Disclosures: The MYSTIC trial was sponsored by AstraZeneca. Dr. Rizvi disclosed royalties related to intellectual property/patents filed by MSKCC and Personal Genome Diagnostics.


Rizvi N et al. WCLC 2019: Abstract OA04.07.